<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057458</url>
  </required_header>
  <id_info>
    <org_study_id>DK100783</org_study_id>
    <secondary_id>R21DK100783</secondary_id>
    <nct_id>NCT02057458</nct_id>
  </id_info>
  <brief_title>Blood Flow and Vascular Function in Cystic Fibrosis</brief_title>
  <acronym>CF-FLOW</acronym>
  <official_title>Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform
      exercise in patients with CF is related to greater death rates, steeper decline in lung
      function, and more frequent lung infections. However, the physiological mechanisms for this
      reduced exercise capacity are unknown. The investigators laboratory recently published the
      first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is
      reasonable to suspect that the blood vessels are involved with exercise intolerance in CF.
      This study will look at how 1) blood flow and 2) artery function contribute to exercise
      capacity in CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most disturbing aspect of Cystic Fibrosis (CF) is the associated premature death. Low
      exercise capacity predicts death in patients with CF and is also associated with a steeper
      decline in lung function and more lung infections. A critical barrier to improving exercise
      tolerance in patients with CF is the investigators lack of knowledge regarding the different
      physiological mechanisms which contribute to their lower exercise capacity. We have
      compelling data to indicate that the blood vessels may contribute to the low exercise
      capacity in CF. The impact of this proof of concept investigation will test Phosphodiesterase
      Type 5 inhibitors (PDE5) inhibitors as a potential therapy in CF and will explore blood flow
      and endothelial function as potential mechanisms which contribute to exercise intolerance in
      CF. Improvements in exercise capacity will not only contribute to a better quality of live
      for patients with CF, it will also increase longevity in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Study: Percentage Flow-Mediated Dilation (FMD)</measure>
    <time_frame>pre-treatment Baseline and 1 hour post-treatment</time_frame>
    <description>FMD determined one hour after ingestion of 50 mg Sildenafil or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Diameter</measure>
    <time_frame>pre-treatment Baseline and following 4 weeks sub-chronic treatment</time_frame>
    <description>Brachial Artery Diameter during FMD (pre-occlusion or &quot;baseline&quot;)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Diameter</measure>
    <time_frame>pre-treatment Baseline and following 4 weeks sub-chronic treatment</time_frame>
    <description>Peak Brachial Artery Diameter during FMD (post-occlusion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change in Diameter</measure>
    <time_frame>pre-treatment Baseline and following 4 weeks sub-chronic treatment</time_frame>
    <description>Absolute change in brachial artery diameter taken from the FMD assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 (% Predicted)</measure>
    <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
    <description>Forced Expiratory Volume in the first second expressed as a percent predicted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 Peak (Absolute)</measure>
    <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
    <description>absolute (L/min) peak oxygen consumption during maximal exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 Peak (Relative)</measure>
    <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
    <description>relative (mL/kg/min) peak oxygen consumption during maximal exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 Peak (Percent Predicted)</measure>
    <time_frame>pre-treatment Baseline and 1 hour post-treatment, and 4 weeks sub-chronic treatment</time_frame>
    <description>Maximal Oxygen consumption expressed as percent predicted taken from maximal exercise test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VE Peak</measure>
    <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
    <description>peak ventilation (L/min) during maximal exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RER Peak</measure>
    <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
    <description>peak respiratory exchange ratio during maximal exercise test</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Acute Study: Sildenafil first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Study: Placebo first, then Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Chronic Study Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil (Acute-1 hour)</intervention_name>
    <description>Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)</description>
    <arm_group_label>Acute Study: Placebo first, then Sildenafil</arm_group_label>
    <arm_group_label>Acute Study: Sildenafil first, then Placebo</arm_group_label>
    <other_name>Viagra</other_name>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil (Subchronic-4 weeks)</intervention_name>
    <description>Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks</description>
    <arm_group_label>Sub-Chronic Study Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill designed to mimic the sildenafil treatment</description>
    <arm_group_label>Acute Study: Placebo first, then Sildenafil</arm_group_label>
    <arm_group_label>Acute Study: Sildenafil first, then Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.

          -  Diagnosis of CF and healthy controls

          -  Men and women (greater than 18 yrs. old)

          -  Resting oxygen saturation (room air) greater than 90%

          -  Forced expiratory volume (FEV1) percent predicted greater than 30%

          -  Patients with or without CF related diabetes

          -  Traditional CF-treatment medications

          -  Ability to perform reliable/reproducible pulmonary function tests (PFT)

          -  Clinically stable for 2 weeks (no exacerbations or need for antibiotic treatment
             within 2 weeks of testing or major change in medical status)

        Exclusion Criteria.

          -  Children less than 17 years old

          -  Body mass less than 20 kg

          -  A diagnosis of pulmonary arterial hypertension (PAH)

          -  FEV1 less than 30% of predicted

          -  Resting oxygen saturation (SpO2) less than 90%

          -  Self-reported to be a smoker

          -  Current use of any vaso-active medications

          -  History of migraine headaches

          -  Pregnant or nursing at the time of the investigation

          -  A clinical diagnosis of cardiovascular disease, hypertension, or CF related diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Harris, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.livep.net</url>
    <description>Laboratory of Integrative Vascular and Exercise Physiology</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <results_first_submitted>March 21, 2020</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Ryan Harris</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>arterial stiffness</keyword>
  <keyword>flow-mediated dilation</keyword>
  <keyword>endothelial function</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>inflammation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>pulmonary function test</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Exercise Capacity</keyword>
  <keyword>CF</keyword>
  <keyword>Muscle Function</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Viagra</keyword>
  <keyword>Revatio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02057458/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acute Study: Sildenafil First, Then Placebo</title>
          <description>In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.</description>
        </group>
        <group group_id="P2">
          <title>Acute Study: Placebo First, Then Sildenafil</title>
          <description>In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.</description>
        </group>
        <group group_id="P3">
          <title>Sub-Chronic Only</title>
          <description>participants who were unable to participate in the acute study due to distance from lab but participated in sub-chronic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Recruited for Participation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Met Inclusion Criteria</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Prior history of migraine headaches</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Acute Study (1 Hour): First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Acute Study (1 Hour): Second Int.</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sub-Chronic Study (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Baseline characteristics reported for the overall study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body fat</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>O2 saturation</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Study: Percentage Flow-Mediated Dilation (FMD)</title>
        <description>FMD determined one hour after ingestion of 50 mg Sildenafil or placebo</description>
        <time_frame>pre-treatment Baseline and 1 hour post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Study: Sildenafil</title>
            <description>FMD % after acute sildenafil treatment</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Placebo</title>
            <description>FMD % after acute placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Study: Percentage Flow-Mediated Dilation (FMD)</title>
          <description>FMD determined one hour after ingestion of 50 mg Sildenafil or placebo</description>
          <units>percent flow mediated dilation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="4.3"/>
                    <measurement group_id="O2" value="7.7" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="4.8"/>
                    <measurement group_id="O2" value="6.6" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Diameter</title>
        <description>Brachial Artery Diameter during FMD (pre-occlusion or &quot;baseline&quot;)</description>
        <time_frame>pre-treatment Baseline and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>&quot;Baseline&quot; artery diameter during FMD taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>Baseline artery diameter during FMD after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Diameter</title>
          <description>Brachial Artery Diameter during FMD (pre-occlusion or &quot;baseline&quot;)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="0.59"/>
                    <measurement group_id="O2" value="3.06" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Diameter</title>
        <description>Peak Brachial Artery Diameter during FMD (post-occlusion)</description>
        <time_frame>pre-treatment Baseline and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Peak artery diameter during FMD taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>Peak artery diameter during FMD after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Diameter</title>
          <description>Peak Brachial Artery Diameter during FMD (post-occlusion)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.60"/>
                    <measurement group_id="O2" value="3.30" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Diameter</title>
        <description>Absolute change in brachial artery diameter taken from the FMD assessment</description>
        <time_frame>pre-treatment Baseline and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Absolute change in artery diameter during FMD taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>Absolute change in artery diameter during FMD after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Diameter</title>
          <description>Absolute change in brachial artery diameter taken from the FMD assessment</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.12"/>
                    <measurement group_id="O2" value="0.27" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 (% Predicted)</title>
        <description>Forced Expiratory Volume in the first second expressed as a percent predicted.</description>
        <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline measures taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Sildenafil</title>
            <description>FEV1 %predicted after acute sildenafil treatment</description>
          </group>
          <group group_id="O3">
            <title>Acute Study: Placebo</title>
            <description>FEV1 %predicted after acute placebo</description>
          </group>
          <group group_id="O4">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>FEV1 %predicted after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (% Predicted)</title>
          <description>Forced Expiratory Volume in the first second expressed as a percent predicted.</description>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="16"/>
                    <measurement group_id="O2" value="75" spread="12"/>
                    <measurement group_id="O3" value="75" spread="16"/>
                    <measurement group_id="O4" value="82" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VO2 Peak (Absolute)</title>
        <description>absolute (L/min) peak oxygen consumption during maximal exercise test</description>
        <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline measures taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Sildenafil</title>
            <description>absolute VO2 peak after acute sildenafil treatment</description>
          </group>
          <group group_id="O3">
            <title>Acute Study: Placebo</title>
            <description>absolute VO2 peak after acute placebo</description>
          </group>
          <group group_id="O4">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>absolute VO2 peak after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>VO2 Peak (Absolute)</title>
          <description>absolute (L/min) peak oxygen consumption during maximal exercise test</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.4"/>
                    <measurement group_id="O2" value="1.7" spread="0.5"/>
                    <measurement group_id="O3" value="1.6" spread="0.5"/>
                    <measurement group_id="O4" value="1.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VO2 Peak (Relative)</title>
        <description>relative (mL/kg/min) peak oxygen consumption during maximal exercise test</description>
        <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline measures taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Sildenafil</title>
            <description>relative VO2 peak after acute sildenafil treatment</description>
          </group>
          <group group_id="O3">
            <title>Acute Study: Placebo</title>
            <description>relative VO2 peak after acute placebo</description>
          </group>
          <group group_id="O4">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>relative VO2 peak after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>VO2 Peak (Relative)</title>
          <description>relative (mL/kg/min) peak oxygen consumption during maximal exercise test</description>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="5.6"/>
                    <measurement group_id="O2" value="29.3" spread="6.1"/>
                    <measurement group_id="O3" value="26.8" spread="6.4"/>
                    <measurement group_id="O4" value="29.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VO2 Peak (Percent Predicted)</title>
        <description>Maximal Oxygen consumption expressed as percent predicted taken from maximal exercise test.</description>
        <time_frame>pre-treatment Baseline and 1 hour post-treatment, and 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline measures taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Sildenafil</title>
            <description>VO2 peak %predicted after acute sildenafil treatment</description>
          </group>
          <group group_id="O3">
            <title>Acute Study: Placebo</title>
            <description>VO2 peak %predicted after acute placebo</description>
          </group>
          <group group_id="O4">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>VO2 peak %predicted after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>VO2 Peak (Percent Predicted)</title>
          <description>Maximal Oxygen consumption expressed as percent predicted taken from maximal exercise test.</description>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="12"/>
                    <measurement group_id="O2" value="77" spread="13"/>
                    <measurement group_id="O3" value="72" spread="13"/>
                    <measurement group_id="O4" value="75" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VE Peak</title>
        <description>peak ventilation (L/min) during maximal exercise test</description>
        <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline measures taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Sildenafil</title>
            <description>VE peak after acute sildenafil treatment</description>
          </group>
          <group group_id="O3">
            <title>Acute Study: Placebo</title>
            <description>VE peak after acute placebo</description>
          </group>
          <group group_id="O4">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>VE peak after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>VE Peak</title>
          <description>peak ventilation (L/min) during maximal exercise test</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="19"/>
                    <measurement group_id="O2" value="81" spread="23"/>
                    <measurement group_id="O3" value="77" spread="24"/>
                    <measurement group_id="O4" value="72" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>RER Peak</title>
        <description>peak respiratory exchange ratio during maximal exercise test</description>
        <time_frame>pre-treatment Baseline, 1 hour post-treatment, and following 4 weeks sub-chronic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline measures taken on preliminary visit before having any treatment.</description>
          </group>
          <group group_id="O2">
            <title>Acute Study: Sildenafil</title>
            <description>RER peak after acute sildenafil treatment</description>
          </group>
          <group group_id="O3">
            <title>Acute Study: Placebo</title>
            <description>RER peak after acute placebo</description>
          </group>
          <group group_id="O4">
            <title>Sub-chronic Study: Sildenafil</title>
            <description>RER peak after sub-chronic (4 weeks) sildenafil treatment</description>
          </group>
        </group_list>
        <measure>
          <title>RER Peak</title>
          <description>peak respiratory exchange ratio during maximal exercise test</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.15"/>
                    <measurement group_id="O2" value="1.17" spread="0.12"/>
                    <measurement group_id="O3" value="1.22" spread="0.13"/>
                    <measurement group_id="O4" value="1.18" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>Overall Study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Harris, PhD</name_or_title>
      <organization>Augusta University</organization>
      <phone>7067215998</phone>
      <email>ryharris@augusta.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

